Endometriosis and the 10-Year Wait

In February 2026, the American College of Obstetricians and Gynecologists did something that, for an organization usually associated with the careful pace of consensus medicine, qualifies as a small revolution. It issued the first standalone US clinical practice guideline dedicated to diagnosing endometriosis, and inside that document, in language unusually candid for a medical body talking about its own field, was this sentence:

It is one thing for an advocate to write that. It is another for ACOG to put it in a guideline.

The new ACOG guidance is the most visible example of a quiet, multi-year shift in how some of the most common drivers of infertility get found, or, more often, don't. Endometriosis. Adenomyosis. A version of PCOS that's been mislabeled for a decade. An undiagnosed early form of premature ovarian insufficiency. These are not exotic conditions. They show up in fertility clinics every week. But they often arrive there years after they should have, and a standard fertility workup is not always equipped to catch them. Here's what the newest research and the newest guidelines say should change, and what to ask for if you're sitting in that workup right now.

For most of the last 30 years, endometriosis was officially diagnosed only by laparoscopic surgery, a procedure most general gynecologists don't perform and most generalist fertility workups don't pre-suppose. The result was a perfect bottleneck: the disease was estimated to affect roughly 10% of reproductive-age women globally, but the only way to confirm it required referral to a surgeon. So referral happened slowly, after years of symptom dismissal, period normalization, and pain that other people called "just bad cramps."

The literature describes that wait in remarkably consistent terms. A 2025 systematic review in BJOG, covering studies from 2018 through 2023, found mean diagnostic delays ranging from 5.4 to 11.4 years, with a pooled average of about 6.8. The largest recent cohort, drawn from France's ComPaRe-Endometriosis registry and published in early 2026, put the average wait at roughly 10 years for endometriosis and 11 years for adenomyosis. The popular "7-to-10-years" shorthand isn't wrong; it's just at the high end of a range that depends on country, cohort, and how rigorously the researchers measured.

A 2025 Frontiers in Medicine meta-analysis summarized what's driving it: symptom normalization, knowledge gaps among generalist providers, and gender bias in how pelvic pain is heard. None of those are individual failures. They're system features.

A decade ago, those system features lived mostly in advocacy material. They are now also in journals and guideline documents. Public stories accelerated that move: Bindi Irwin's 2023 disclosure of a decade of dismissal, Lena Dunham's 2018 Vogue hysterectomy essay, Padma Lakshmi's 23-year wait, and Abby Norman's memoir Ask Me About My Uterus collectively did something that's hard to do inside a single doctor's appointment: they made the diagnostic wait legible to people who hadn't lived it.

What's actually shortening it, though, is a slow, expensive, and uneven update of the workup itself.

The big change in the new ACOG guidance, and in the 2022 ESHRE guideline, and the updated NICE NG73 in late 2024, is the formal abandonment of laparoscopy as the diagnostic gold standard.

Translated: a doctor no longer needs to find surgical evidence of endometrial-like tissue outside the uterus to diagnose you with endometriosis. A presumptive diagnosis, based on symptoms and a careful clinical exam, is now considered appropriate. ACOG, ESHRE, and NICE have all said so within the last four years.

That's a meaningful shift for anyone in a fertility workup. The ASRM's 2012 committee opinion on endometriosis and infertility, still ASRM's most recent word on the topic, notes that infertile women are six to eight times more likely to have endometriosis than fertile women, and that prevalence in women undergoing laparoscopy for infertility evaluation runs as high as 50%. That isn't an obscure statistic. That's an "if you're sitting in a fertility clinic, the odds are real" statistic.

The catch: ASRM has not updated that opinion since 2012. So an American patient at a fertility clinic in 2026 is, in a sense, in the gap. ACOG, ESHRE, and NICE have moved to symptom-based diagnosis; some fertility practices still default to the older surgical-confirmation framing.

"Endometriosis is a whole-body disease," says Dr. Hugh S. Taylor, chair of obstetrics and gynecology at Yale and one of the researchers developing a blood-based microRNA test for non-invasive endometriosis diagnosis. That single reframe is part of why generalist-only workups so often miss it.

Adenomyosis, endometrial tissue growing into the muscular wall of the uterus rather than outside it, is the condition the fertility workup historically did even worse with. It shares symptoms with endometriosis. The two coexist often enough that some specialists consider them clinical siblings. Adenomyosis used to be diagnosable only after hysterectomy, which is not a useful test for someone trying to conceive.

The numbers now look like this:

·      A 2020 cross-sectional study in Reproductive BioMedicine Online found imaging evidence of adenomyosis in roughly 24% of women undergoing fertility evaluation when ultrasound was performed systematically. About one in four.

·      A 2023 meta-analysis in the International Journal of Gynecology and Obstetrics put standard transvaginal ultrasound's pooled sensitivity at about 75%, meaning roughly one in four cases is missed by the first-line imaging test, with miss rates rising significantly when sonographers aren't using 3D protocols or MUSA criteria.

·      A 2017 meta-analysis in Fertility and Sterility30484-3/fulltext) reported that adenomyosis lowers clinical pregnancy by about a third and roughly doubles miscarriage rates in IVF.

A more recent 2026 propensity-score study on focal disease found no significant effect on most IVF outcomes, which is part of why a careful clinician will ask about type of adenomyosis, not just presence or absence. Severity and pattern matter.

The upshot for the fertility workup is still simple, though. If you've been told a transvaginal ultrasound is clean and the "unexplained infertility" label has been suggested, the math says there's a reasonable chance adenomyosis is in the room and hasn't been seen yet. An MRI, or a repeat ultrasound with a sonographer specifically trained in adenomyosis imaging, is a legitimate next step to discuss. Anyone who has spent time in r/Adenomyosis already knows this: the most common story in that community is a clean first scan followed by a positive second one ordered by a specialist who was specifically looking.

Polycystic ovary syndrome has the opposite problem of endometriosis and adenomyosis. It's almost certainly over-diagnosed in some populations and under-diagnosed in others. And the diagnostic criteria have shifted twice in the last decade.

The 2023 International Evidence-Based PCOS Guideline, led by Dr. Helena Teede at Monash University and endorsed by 39 organizations including ASRM, refined the older 2003 Rotterdam criteria in two ways that matter. First, it allows AMH testing to substitute for ovarian ultrasound when confirming polycystic morphology. Second, it tightens what counts as androgen excess and ovulatory dysfunction.

When researchers re-applied the newer criteria to women previously diagnosed under Rotterdam, only about three-quarters still met the stricter definition. The remaining quarter, patients carrying a PCOS diagnosis but no longer meeting the criteria, sit in a quiet limbo. The label may be shaping treatment that doesn't fit.

For anyone navigating fertility care, a PCOS diagnosis from years ago is worth re-evaluating against the current guideline. Phenotype matters, particularly for ovulation induction decisions.

POI is the diagnosis people most quietly fear: ovarian function declining before age 40. The 2024 ESHRE evidence-based guideline, endorsed by ASRM in 2025, simplified the criteria. Where the older definition required at least three months of amenorrhea plus repeated FSH levels above 30 IU/L, the new standard accepts four months of irregular cycles paired with FSH above 25 IU/L in someone under 40.

That sounds technical. The practical translation is that more women, earlier, now meet the diagnostic threshold for POI. The guideline also explicitly notes that AMH should not be used as the primary diagnostic test, useful context if you've been quoted an AMH number and given a verbal diagnosis without further workup.

Earlier diagnosis matters because POI's implications run well beyond fertility: bone health, cardiovascular health, hormone replacement decisions. The fertility window is one piece of a longer conversation that deserves to start at the right time.

The shared throughline across all four conditions is a kind of system lag: the research has moved faster than many individual practices have updated. A standard couples' fertility workup, especially at a high-volume clinic, often defaults to a familiar sequence (bloodwork, transvaginal ultrasound, semen analysis, hysterosalpingogram) without specifically chasing the conditions where diagnostic delay is the central feature.

That's not always negligence. It's frequently just the default, set when the science said something different.

1.     If my ultrasound is normal, what's the threshold for considering empiric endometriosis treatment under the new ACOG and NICE guidelines?

2.    Has the sonographer specifically evaluated for adenomyosis using MUSA criteria or 3D protocols, or only ruled out the obvious causes?

3.    If I was diagnosed with PCOS more than five years ago, does my history still meet the 2023 international criteria?

4.    Could my cycle irregularities meet the new ESHRE criteria for POI, and what FSH testing schedule would clarify it?

5.    If something is being missed, what's the next step (MRI, a specialist referral, or a second-opinion consult) that you would recommend?

The encouraging part of the story is that the change is real. ACOG, ESHRE, and NICE have all moved within four years. The Yale microRNA work is one of several non-invasive diagnostic candidates in trials. Adenomyosis is finally being studied as a fertility issue rather than a hysterectomy issue. PCOS phenotyping is more sophisticated than it's ever been. POI criteria are catching more women earlier. The AMA Journal of Ethics' February 2025 piece on policy-level reform makes the case that the next round of fixes is structural, not just clinical.

The discouraging part is that all of that lives upstream of any individual appointment. Whether it shows up in your workup depends on your clinic, your insurer, your geography, and what you happen to ask for.

The wait is shortening, slowly, unevenly, but measurably. And one of the durable lessons of the last 30 years of advocacy from people like Padma Lakshmi and writers like Abby Norman is that the patient asking the next question is usually the reason the workup gets re-opened. The new guidelines exist in part because patients refused to stop asking. They're a permission slip, not a finish line.

If your instinct is telling you something has been missed, it isn't paranoia. Increasingly, the literature agrees with you.

·      ACOG, Clinical Practice Guideline 11: Diagnosis of Endometriosis (2026)

·      WHO, Endometriosis Fact Sheet

·      ESHRE, Endometriosis Guideline (2022) and POI Guideline (2024)

·      Monash University, International PCOS Guideline (2023)

·      Endometriosis Foundation of America, endofound.org. Padma Lakshmi and Dr. Tamer Seckin's nonprofit, with a directory of excision-trained surgeons.